Sessions Include Integrated Data From Phase 3 Studies of Trius' Experimental Drug Tedizolid as Well as Findings From Pre-Clinical Gram-Negative Program and cfr Resistance Studies
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc.
Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Trius Therapeutics, Inc.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Trius Therapeutics (“Trius”...
Former Attorney General of Louisiana Charles C. Foti, Jr.
You'll never make money just following the Federal Reserve, Cramer said.
Rigrodsky & Long, P.A.
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Trius Therapeutics, Inc.
Jim Cramer looks at the implications of the latest biotech deal, Cubist acquiring Trius, and the implications for the biotech sector.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Trius Therapeutics, Inc.
U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.
Levi & Korsinsky is investigating the Board of Directors of Trius Therapeutics, Inc.
Cubist announces two acquisitions in one day.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc.
Investors in Trius Therapeutics Inc. saw new options begin trading this week, for the March 2014 expiration.
Five Below is Cramer's favorite dollar store and Trius Therapeutics is a biotech to watch.
With stocks back on the front page, there are plenty of profits yet to be made, Cramer said.
StockMarketMentor.com founder Dan Fitzpatrick details how to play three stocks Jim Cramer discussed on CNBC's "Mad Money" last night.
The stock market is doing better than investors think, Cramer asserts.
Peer-Reviewed Results Suggest No Clinically Significant Interactions Between Trius' Experimental Antibiotic Tedizolid and a Commonly Used Class of Medications
Investors considering a purchase of Trius Therapeutics Inc. shares, but cautious about paying the going market price of $7.92/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Industry Veteran Brings Legal, Transactional and Commercial Compliance Expertise
The pace of deals among developers of antibiotics is about to ramp higher.
